Compass Therapeutics announced positive Phase 2/3 trial results for tovecimig, showing significant improvement in progression-free survival and overall response rate for biliary tract cancer patients. The drug received Orphan Drug Designation and the company plans a BLA submission later this year. Additionally, Phase 1 studies for CTX-8371 and CTX-10726 bispecific antibodies are progressing, with data presentations expected in 2026. The company holds $195 million in cash, supporting operations into 2028.
The Dolphin Company's current management proposed selling its main assets in Mexico to Delphinus Blue Planet, a Grupo Xcaret subsidiary, for $20 million. This deal would give Delphinus control over more than 90% of dolphin habitats in Mexico, creatin...
Johnson & Johnson has reached a historic $5.5 billion settlement to resolve claims from about 70,000 women and families alleging its talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and meso...
Bitcoin fell about 2.7% to around $63,200 following the U.S. market close, dragged down by a sharp 10% drop in South Korea's Kospi index, which hit its lowest since April. The U.S. Senate postponed a vote on the CLARITY Act, delaying crypto regulator...
AI coding startup Cursor has introduced Cursor Start, a ₹649 ($7) monthly subscription tailored for India, priced below its $20 Pro plan. India is Cursor's third-largest market with rapid user growth, making it a strategic focus for expansion. The pl...
Catalyst Acquisition Corp. announced the pricing of its initial public offering (IPO) at $10 per unit, raising $200 million by offering 20 million units. The units, each including one Class A ordinary share and a partial share right, will begin tradi...
